Related Experiment Videos
Experimental and clinical results with intraperitoneal cisplatin
Seminars in Oncology
|September 1, 1985
Summary
Intraperitoneal cisplatin offers remission for ovarian cancer patients but has toxicity. Sodium thiosulfate may mitigate side effects, and new platinum agents and rescue therapies are under investigation.
Area of Science:
- Oncology
- Pharmacology
Background:
- Intraperitoneal cisplatin therapy can induce complete remission in up to 30% of ovarian cancer patients with minimal residual disease.
- However, this treatment is associated with significant toxicity, including nephrotoxicity, hematologic complications, and neurotoxicity, limiting maximal therapeutic dosages.
Purpose of the Study:
- To explore strategies for mitigating the toxicity of intraperitoneal cisplatin therapy.
- To investigate alternative platinum chemotherapeutic agents and rescue agents to improve treatment outcomes and patient tolerance.
Main Methods:
- Review of existing data on intraperitoneal cisplatin therapy and its complications.
- Investigation of the protective effects of sodium thiosulfate on renal and hematologic functions during cisplatin therapy.
- Exploration of novel platinum agents and pharmacodynamic/pharmacokinetic studies of intraperitoneal administration.
Main Results:
- Sodium thiosulfate has demonstrated efficacy in protecting renal function and reducing hematologic complications associated with cisplatin therapy.
- Neurotoxicity remains a significant challenge in achieving maximal therapeutic doses of cisplatin.
Conclusions:
- While intraperitoneal cisplatin can be effective, its toxicity necessitates the development of supportive care strategies.
- Ongoing research focuses on novel platinum agents and rescue therapies to enhance the safety and efficacy of ovarian cancer treatment.